Filing Details

Accession Number:
0001179022-19-000032
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-06-03 17:28:22
Reporting Period:
2019-05-29
Accepted Time:
2019-06-03 17:28:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1133416 Galectin Therapeutics Inc GALT Pharmaceutical Preparations (2834) 043562325
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1694903 E Richard Uihlein 12575 Uline Drive
Pleasant Prairie WI 53158
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-05-29 500,000 $5.00 3,128,489 No 4 M Direct
Common Stock Acquisiton 2019-05-31 4,672,896 $4.28 7,801,385 No 4 P Direct
Common Stock Acquisiton 2019-05-31 7,710 $4.28 27,710 No 4 P Indirect By Ed Uihlein Family Foundation
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 P Direct
No 4 P Indirect By Ed Uihlein Family Foundation
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Purchase Warrant (right to buy) Disposition 2019-05-21 500,000 $0.00 500,000 $5.00
Common Stock Common Stock Purchase Warrant (right to buy) Acquisiton 2019-05-29 15,576,322 $0.00 1,168,253 $7.00
Common Stock Common Stock Purchase Warrant (right to buy) Acquisiton 2019-05-31 25,700 $0.00 1,927 $7.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
966,204 2017-06-22 2023-12-22 No 4 M Direct
15,576,322 2019-11-30 2026-05-31 No 4 P Direct
25,700 2019-11-23 2026-06-03 No 4 P Indirect
Footnotes
  1. The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.
  2. Each warrant is exerciseable for 0.075 shares of Common Stock of the Company.